Last updated: 2026-10-13 10:26:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Tiziana Life Sciences Ltd (TLSA) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1,10, with a market capitalisation of $151,44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,76 to $2,20. This page covers its latest market performance, valuation, price trends and company information.
$151,44M | |
$1,10 | |
$16,79 | |
$0,41 | |
$1,09 | |
125,00 | |
761,17K | |
-- | |
$2,20 | |
$0,76 | |
-- | |
-- |
Tiziana Life Sciences Ltd (TLSA) is trading at $1,10 in pre-market trading as of 2026-10-13 10:17:00, up 0,92% ($0,01) from the previous close of $1,09
Pre-market trading shows how investors are pricing TLSA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Tiziana Life Sciences Ltd (TLSA) moved from $1,12 to $1,10, representing a decline of 1,79% ($0,02).
The stock traded between $1,05 and $1,25 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 738,85 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 23,5%
TLSA is currently trading at $1,10, placing it 23,5% of the way from its 52-week low of $0,76 to its 52-week high of $2,20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tiziana Life Sciences Ltd (TLSA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.